Suppr超能文献

与中重度哮喘患者的生物制剂依从性和结局相关的因素。

Factors Related to Biologic Adherence and Outcomes Among Moderate-to-Severe Asthma Patients.

机构信息

Department of Population Health Sciences, Duke University School of Medicine, Durham, NC.

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC.

出版信息

J Allergy Clin Immunol Pract. 2022 Sep;10(9):2355-2366. doi: 10.1016/j.jaip.2022.05.022. Epub 2022 May 28.

Abstract

BACKGROUND

Adherence barriers to asthma biologics may not be uniform across administration settings for patients with moderate-to-severe asthma.

OBJECTIVE

To examine differences in asthma biologic adherence and associated factors, as well as association with a 1-year all-cause emergency department (ED) visit, across administration settings.

METHODS

A retrospective study of biologic naïve moderate-to-severe asthma patients with initial biologic therapy between January 1, 2016, and April 30, 2020, in the Optum Clinformatics Data Mart was performed. Three administration settings were identified: Clinic-only (outpatient office/infusion center), Home (self-administration), and Hybrid setting (mixture of clinic and self-administration). Asthma biologic adherence was the proportion of observed over expected biologic dose administrations received within 6 months from initial therapy. Factors associated with adherence were identified by administration setting, using Poisson regression analyses. A relationship between a 1-year all-cause ED visit and adherence was assessed for each administration setting using Cox regression analyses.

RESULTS

The study cohort was 3932 patients. Biologics adherence was 0.75 [0.5, 1] in Clinic setting, the most common administration setting, and 0.83 [0.5, 1] in both Home and Hybrid settings. Specialist access was consistently associated with better biologic adherence, whereas Black race, Hispanic ethnicity, lower education, Medicare only insurance, and higher patient out-of-pocket cost were associated with worse biologic adherence in some settings. In the Hybrid setting, hazard for a 1-year all-cause ED visit decreased with biologic adherence.

CONCLUSIONS

Asthma biologic adherence varied by administration setting. Efforts to improve asthma biologic adherence should consider promoting self-administration when beneficial, improving prior specialist access, and targeting patients with higher risk of suboptimal adherence particularly Black and Hispanic patients.

摘要

背景

在中度至重度哮喘患者中,不同的给药环境下,哮喘生物制剂的用药依从性障碍可能并不一致。

目的

检测不同给药环境下哮喘生物制剂的用药依从性及相关因素差异,以及与 1 年全因急诊就诊(ED)的相关性。

方法

本研究为回顾性研究,纳入了 2016 年 1 月 1 日至 2020 年 4 月 30 日在 Optum Clinformatics Data Mart 中接受初始生物制剂治疗的生物制剂初治的中重度哮喘患者。共识别出 3 种给药环境:仅诊所(门诊/输液中心)、家庭(自我管理)和混合(诊所和自我管理的混合)。哮喘生物制剂的依从性是指在初始治疗后 6 个月内,观察到的生物制剂剂量与预期剂量之比。通过泊松回归分析,按给药环境确定与依从性相关的因素。对每种给药环境下 1 年全因 ED 就诊与依从性的关系,均采用 Cox 回归分析进行评估。

结果

研究队列纳入了 3932 名患者。最常见的给药环境即诊所环境中的生物制剂依从性为 0.75 [0.5,1],家庭和混合环境中的生物制剂依从性均为 0.83 [0.5,1]。专科医生的可及性与更好的生物制剂依从性始终相关,而黑人种族、西班牙裔、较低的教育水平、仅拥有医疗保险和较高的患者自付费用,与某些环境下的生物制剂依从性较差相关。在混合环境中,生物制剂依从性越高,1 年全因 ED 就诊的风险越低。

结论

哮喘生物制剂的依从性因给药环境而异。为了提高哮喘生物制剂的依从性,应该考虑在有利的情况下促进自我管理,改善专科医生的可及性,并针对依从性较差风险较高的患者,特别是黑人及西班牙裔患者进行治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验